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Hepcidin, a peptide hormone that decreases intestinal iron absorption and macrophage iron
release, is a potential drug target for patients with iron overload syndromes because its levels
are inappropriately low in these individuals. Endogenous stimulants of Hepcidin transcrip-
tion include bone morphogenic protein 6 (BMP6) and interleukin-6 (IL-6) by effects on
mothers against decapentaplegic homolog (Smad)4 or signal transducer and activator of
transcription (Stat)3, respectively. We conducted a small-scale chemical screen in zebrafish
embryos to identify small molecules that modulate hepcidin expression. We found that treat-
ment with the isoflavone, genistein, from 28-52 hours postfertilization in zebrafish embryos
enhanced Hepcidin transcript levels, as assessed by whole-mount in situ hybridization and
quantitative real-time reverse-transcriptase polymerase chain reaction. Genistein’s stimulatory
effect was conserved in human hepatocytes: Genistein treatment of HepG2 cells increased
both Hepcidin transcript levels and promoter activity. We found that genistein’s effect on
Hepcidin expression did not depend on estrogen receptor signaling or increased cellular iron
uptake, but was impaired by mutation of either BMP response elements or the Stat3-binding
site in the Hepcidin promoter. RNA sequencing of transcripts from genistein-treated hepato-
cytes indicated that genistein up-regulated 68% of the transcripts that were up-regulated by
BMP6; however, genistein raised levels of several transcripts involved in Stat3 signaling that
were not up-regulated by BMP6. Chromatin immunoprecipitation and ELISA experiments
revealed that genistein enhanced Stat3 binding to the Hepcidin promoter and increased
phosphorylation of Stat3 in HepG2 cells. Conclusion: Genistein is the first small-molecule ex-
perimental drug that stimulates Hepcidin expression in vivo and in vitro. These experiments
demonstrate the feasibility of identifying and characterizing small molecules that increase
Hepcidin expression. Genistein and other candidate molecules may subsequently be devel-
oped into new therapies for iron overload syndromes. (HEPATOLOGY 2013;58:1315-1325)
H
epcidin is a transcriptionally regulated peptide
hormone1 that is expressed primarily in the
liver and excreted in urine. It is up-regulated
in response to inflammation2,3 or iron overload4 and
down-regulated in response to increased erythropoiesis,
iron deficiency, or hypoxia.2 Hepcidin decreases intestinal
iron absorption and macrophage iron release by causing
internalization of the iron exporter, ferroportin1.5-7
Patients with hereditary hemochromatosis8 or thalasse-
mia9-11 exhibit inappropriately low levels of hepcidin and
increased intestinal iron absorption, despite the presence
of systemic iron overload.12 Although treatment for iron
overload is currently based on removal of blood or
administration of iron chelators, it may be possible to
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prevent iron overload in patients with genetic predisposi-
tion if nontoxic small molecules can be administered that
increase transcription of Hepcidin.
Iron overload4 and inflammation2,3 stimulate hepci-
din expression by triggering the mothers against decap-
entaplegic homolog (Smad)-signaling or signal
transducer and activator of transcription (Stat)-signal-
ing pathways, respectively. It has been demonstrated
that exposing human hepatocytes to bone morphogenic
proteins (BMPs) up-regulates Hepcidin transcription by
increasing Smad4 binding at Smad4-binding motifs,
termed BMP response elements (BREs), in the Hepci-
din promoter.13-16 BMPs are members of the trans-
forming growth factor beta (TGF-b) family that signal
by binding to transmembrane receptor complexes with
serine-threonine kinase activity.17 Recent studies in
mouse models18-21 indicate that BMP6 is the most
likely physiologic regulator of hepcidin transcription in
response to iron loading. Inflammatory stimuli, on the
other hand, trigger increased serum interleukin-6 (IL-
6) levels.22 IL-6 stimulates Hepcidin expression23
through increased Stat3 binding to a Stat3-responsive
element in the Hepcidin promoter.24-27
We have developed the zebrafish embryo (Danio
rerio) as an in vivo model to study hepcidin expression.
Hepcidin expression begins at 36 hours postfertilization
(hpf ) in the zebrafish embryo and is responsive to iron
levels and BMPs during embryonic development.28 To
demonstrate that zebrafish embryos can be used to
identify small-molecule modulators of Hepcidin expres-
sion, we screened a small number of naturally occur-
ring isoflavones and related molecules for their effect
on Hepcidin expression. We chose to evaluate isofla-
vones because they are nontoxic and are known to
have kinase inhibitory actions.29 In this way, we identi-
fied genistein as the first small-molecule experimental
drug to increase Hepcidin expression in vivo. We found
that genistein also increased Hepcidin expression in
cultured human hepatocytes (HepG2 cells). Using
luciferase reporter assays, RNA sequencing (RNA-seq),
and chromatin immunoprecipitation (ChIP), we dem-
onstrated that genistein increases Hepcidin expression
in a Smad4-dependent and Stat3-dependent manner.
Materials and Methods
Zebrafish Embryo Chemical Treatment, In Situ
Hybridization, and Complementary DNA Prepara-
tion. Ethical approval was obtained from the institu-
tional animal care and use committee of Beth Israel
Deaconess Medical Center (Animal Welfare Assurance
#A3153-01; Boston, MA) in accord with national and
international guidelines. Zebrafish were maintained as
previously described.30 Pools of 20 embryos were treated
either with 7 lM of genistein, genistin, apigenin, daiz-
dein, or estradiol and/or 40 lM of dorsomorphin (all
obtained from Sigma-Aldrich, St. Louis, MO) or vehicle
alone (1% dimethyl sulfoxide; DMSO) from 28 to 52
hpf. Embryos were then fixed in 4% paraformaldehyde
in phosphate-buffered saline for whole-mount in situ
hybridization using anti-sense zebrafish hepcidin or
FOXA3 probes, as previously described.31 O-dianisidine
staining for hemoglobin and flow cytometry were per-
formed as described in the Supporting Materials. Repre-
sentative embryos were photographed at 1003
magnification with a BX51 compound microscope
(Olympus, Center Valley, PA) and a Q-capture 5 digital
camera (QImaging, Surrey, British Columbia, Canada).
Expression analysis was conducted at the specified time
points, by anesthetizing pools of 20 embryos with tri-
caine, followed by storage in RNAlater (Ambion, Life
Technologies, Grand Island, NY). RNA extraction and
generation of complementary DNA (cDNA) were per-
formed as previously described.6,32
Cell Culture and Chemical Treatment. The
human hepatocarcinoma cell line, HepG2 (American
Type Culture Collection, Manassas, VA), was main-
tained in alpha-minimum essential medium (a-MEM)/
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10% certified endotoxin-free fetal bovine serum (FBS)/
1% penicillin-streptomycin (Life Technologies) at 37C
in 5% CO2. HepG2 cells were seeded onto 12-well
tissue-culture-treated plates at a density of 4 3 105 cells
per well. Twenty-four hours later, the culture medium
was changed to low-serum medium (a-MEM/1% FBS).
After 8 hours of equilibration, cells were then treated for
the specified time periods with genistein, genistin, apige-
nin, daizdein, dorsomorphin (each at 10 lM), estradiol
(0.001-100 lM), ICI 182,780 (100 lM) (all from
Sigma-Aldrich), IL-6 20 or 100 ng/mL, BMP6 50 ng/
mL (both from R&D Systems, Minneapolis, MN), or
vehicle only (1% DMSO). All the samples included 1%
DMSO to control for any potential effects of the vehicle.
Quantitative Real-Time Reverse Transcriptase Po-
lymerase Chain Reaction. After 18 or 24 hours of
treatment, cells were harvested for extraction of total
RNA using the RNeasy Mini Kit (Qiagen, Valencia,
CA), according to the manufacturer’s instructions.
DNA was eliminated by on-column RNase-free DNase
treatment. Reverse transcription was performed using
RNA (300 ng), oligo-dT, and Superscript II reverse
transcriptase (RT; Life Technologies) in a 20-lL reac-
tion, which was later diluted to 100 lL.
Ten percent of each RT reaction was used for a single
50-lL quantitative real-time RT-PCR (polymerase chain
reaction) assay using Taqman Universal PCR Master
Mix or SYBR Green PCR Master Mix (both from Life
Technologies). Primer and probe sequences are given in
Supporting Table 1. Transcript levels were calculated as
fold increases over the control sample. The described
reactions failed to amplify the nontemplate controls or
RNA samples that were not treated with RT.
Transferrin and Nontransferrin-Bound 55Fe
Uptake Assays and Ferritin Enzyme-Linked Immu-
nosorbent Assay. Methods for transferrin and non-
transferrin-bound 55Fe uptake assays and ferritin
enzyme-linked immunosorbent assay (ELISA) are pro-
vided in the Supporting Materials.
Dual Luciferase Assay. HepG2 cells were trans-
fected with pGL4.17 Hepc, 3 kilobases (kb) of the
human Hepcidin promoter upstream of the firefly lu-
ciferase reporter gene, or mutated versions of the con-
struct with point mutations in the Stat3-binding site,
the BREs, or both the BRE-binding and the Stat3-
binding site.33 Additional details are provided in the
Supporting Materials. The Hepcidin reporter constructs
were donated by Drs. Ganz and Nemeth (Division of
Pulmonary and Critical Care, University of California,
Los Angeles). As a control, HepG2 cells were cotrans-
fected with Renilla luciferase under control of the cy-
tomegalovirus promoter (pRL-CMV; Promega,
Madison, WI). Transiently transfected cells were
treated for 6 hours with genistein (10 lM), BMP6 (50
ng/mL), or vehicle (1% DMSO) only. The Dual-Glo
Luciferase Assay (Promega) was then performed
according to the manufacturer’s instructions.
Statistical Analysis for Quantitative PCR, Iron
Uptake, Luciferase, ChIP, and ELISA. All data
shown are means6 standard error from the mean.
Data analysis was performed using Prism 5.0 (Graph-
Pad Software, Inc., La Jolla, CA). For comparisons of
Table 1. KEGG Pathway Analysis of Genes That Were Up-Regulated by Genistein
Term Count P Value Genes
Benjamini-
Hochberg
Statistic
hsa03010/
ribosome
37 0.00E-01 RPL18, RPL13, RPS3AP47, RPL35, RPLP2, RPL36, RPL37, RPS19P3, RPL38, RPLP0P2, RPS27, RPL32,
RPS11P5, RPLP1, RPL3, RPL29P26, RPL12, RPL7A, RPL10A, RPS20, RPS21, RPS13P2, RPS23,
RPS15P5, RPSA, RPS16P10, RPS9, RPL27, RPL23A, RPSAP8, RPS3P3, RPS6, RPS5, RPL28, RPS8,
RPL18A, RPL37A, UBA52
0.00E-01
hsa04110/
cell cycle
36 0.00E-01 MAD1L1, FZR1, E2F4, PKMYT1, ANAPC11, SFN, PTTG1, ZBTB17, TGFB1, RBX1, MCM7, CDKN2B, TFDP2,
MYC, CCNA2, BUB3, CUL1, ANAPC2, CREBBP, CDC20, CDK7, CDC25C, MCM5, CDC25B, CCNB1,
CDKN1A, CCND1, CDKN1B, YWHAH, CCNB2, PLK1, ANAPC7, ABL1, MAD2L2, GADD45B, GADD45A
0.018
hsa03040/
spliceosome
36 0.00E-01 HNRNPA1L2, CHERP, CCDC12, NHP2L1, U2AF2, LSM7, SF3B5, BUD31, XAB2, SART1, CTNNBL1, SFRS4,
DHX38, PRPF8, PCBP1, SFRS9, PQBP1, SNRNP70, ACIN1, LSM2, PRPF40B, DDX42, DHX8, SNRPA1,
EFTUD2, SF3A2, SF3A1, EIF4A3, PPIE, SNRNP200, SNRPB, SNRPA, THOC4, PHF5A, PUF60, SNRPG
0.014
hsa05221/
acute myeloid
leukemia
21 0.00E-01 HRAS, PPARD, MAP2K1, MAP2K2, RELA, STAT5B, PIK3CD, PIM1, RPS6KB2, BAD, TCF7L2, STAT3, JUP,
EIF4EBP1, CCND1, ARAF, IKBKG, RARA, RUNX1, MYC, AKT2
0.011
hsa04142/
lysosome
33 0.01E-01 SGSH, AP1M1, CLTB, AP1B1, LGMN, HEXA, HEXB, ATP6V0B, CTSL1, ATP6V0C, CD68, MAN2B1, ATP6V0D1,
PSAP, ATP6V1H, AP4M1, CD63, AP4S1, CD164, LAMP1, NPC1, GLA, IGF2R, GAA, ATP6V0A1, CTSD,
NEU1, CTSC, CTSB, GGA1, GGA2, CTSH, GGA3
0.021
hsa05220/chronic
myeloid
leukemia
23 0.00153 HRAS, CTBP1, BCR, MAP2K1, MAP2K2, RELA, STAT5B, PIK3CD, BCL2L1, BAD, TGFB1, CCND1, CDKN1A,
CDKN1B, GAB2, ARAF, IKBKG, SHC1, ABL1, RUNX1, SHC2, MYC, AKT2
0.046
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two groups, two-tailed Student t tests were performed
comparing experimental treatment to DMSO treat-
ment. For comparisons of three or more groups, Krus-
kal-Wallis’ test was performed on raw data or natural
logs of raw data. If P< 0.05, pairwise comparisons
were made with two-tailed Student t tests. Compari-
sons where P< 0.05 were deemed significant.
RNA-seq. As described above, HepG2 cells were
cultured in 12-well plates, shifted to low-serum condi-
tions, and treated with DMSO (1%), BMP6 (50 ng/
mL), or genistein (10 lM) for 18 hours. The numbers
of biological replicates were 3, 2, and 3, respectively.
Details are provided in the Supporting Materials. Dif-
ferential expression for BMP6-treated or genistein-
treated biological replicates, compared to DMSO-
treated controls, was determined using the Cufflinks
tool, Cuffdiff. The criteria for differential expression
were as follows: a log2 fold-change of >0.58 or
<20.58 and a Q value <0.05, when compared to the
control condition. We also required that the differen-
tially expressed genes used for downstream analysis
had a fragments per kilobase of exon per million frag-
ments mapped (FPKM) >0.1 in at least one of the
conditions. Enrichments in particular biological proc-
esses, pathways, and functions were calculated statisti-
cally using the DAVID annotation database.34 Prism
5.0 was used to perform linear regression analysis of
the correlation between the natural log of gene expres-
sion changes measured by RNA-seq and quantitative
real-time RT-PCR. All RNA-seq data have been depos-
ited in the Gene Expression Omnibus database (http://
www.ncbi.nlm.nih.gov/geo).
ChIP Followed by Quantitative PCR. HepG2
cells were seeded on 150-mm2 plates and cultured to
reach a cell density of 5 3 107 cells per plate. Eight
hours before treatment, cells were washed and shifted
to low-serum media (a-MEM/1% FBS). Chemicals
were added to achieve either 1% DMSO, 10 lM of
genistein, 50 ng/mL of BMP6, or 20 ng/mL of IL-6.
After 24 hours of treatment, cells were cross-linked by
adding formaldehyde to reach a final concentration of
1%. After reversal of cross-linking, cells were lysed,
sonicated, and chromatin was immunoprecipitated
with antibody (Ab)-coated Dynabeads Protein G (Life
Technologies). Additional details are provided in Sup-
porting Materials. The Abs used were anti-Stat3 (sc-
7154) and anti-rabbit immunoglobulin (Ig)G (sc-
2027) (both from Santa Cruz Biotechnology, Santa
Cruz, CA). DNA was eluted from the beads and used
as a template in a quantitative PCR reaction using pri-
mers (Supporting Table 1) to amplify the proximal
BMP/Stat response element, located 84 nucleotides
before the Hepcidin start site.25 The data were reported
as fold increase in binding of the specific Ab over
binding to nonspecific Ig.
Stat3 ELISA. Adherent HepG2 cells (2 3 104
cells per well of a 96-well plate) were incubated in
serum-free a-MEM for 16 hours, followed by the
addition of the following treatments: DMSO (1%);
genistein (10 lM); or IL-6 (100 ng/mL). Cells were
fixed in 4% formaldehyde after 0-60 minutes of treat-
ment. Detection of Stat3 and phospho-Stat3 (pStat3)
was performed using the Stat3 Colorimetric In-Cell
ELISA Kit (Thermo Fisher Scientific Pierce, Rockford,
IL), according to the manufacturer’s instructions.
Results
Genistein Increases hepcidin Expression in
Zebrafish Embryos. Because we had previously dem-
onstrated evolutionarily conserved aspects of hepcidin
regulation in zebrafish embryos,28 we used zebrafish
embryos to evaluate naturally occurring isoflavones
(genistein and daizdein), genistin (the inactive gluco-
side form of genistein), or a flavone (apigenin) as
potential modulators of mammalian Hepcidin expres-
sion. Because genistein, daizdein, and apigenin have
estrogenic effects, we also evaluated estradiol. Embryos
were treated from 28 to 52 hpf with the chemicals,
each at 7 lM, followed by fixation for whole-mount
in situ hybridization (Fig. 1A) or quantitative real-time
RT-PCR (Fig. 1B) to assess hepcidin RNA levels. We
found that genistein treatment was associated with
increased intensity of hepcidin expression (Fig. 1A,B)
and an expanded domain of expression extending from
the liver into the proximal intestine in 100% of 36
embryos, whereas treatment with apigenin, daizdein,
estradiol, or genistin did not increase either intensity
or extent of expression. However, treatment with the
BMP receptor antagonist, dorsomorphin, abrogated
genistein’s effect on hepcidin expression (Fig. 1A).
The genistein-induced increase in hepcidin transcript
levels was modest (Fig. 1B), related to decreased liver
size and only a slight increase in hepatocyte-specific hep-
cidin expression (Supporting Figs. 1-3). This may
explain why, despite the increase in hepcidin expression,
staining for hemoglobin (Supporting Fig. 4) did not
reveal anemia in any of the genistein-treated embryos
(n5 50).
Genistein Increases Hepcidin Expression in
HepG2 Cells. To evaluate whether genistein exerted a
conserved effect on human hepatocytes, we tested the
compounds in human hepatoma (HepG2) cells. We
found that genistein produced a five-fold increase in
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Hepcidin expression, as measured by quantitative real-
time RT-PCR (Fig. 1C) that was not reproduced by
treatment with the other small molecules. The effect
was dose dependent (Fig. 1D), with higher increases in
Hepcidin expression noted at 20 than 10 lM. In
contrast, no significant increase in Hepcidin expression
was noted after treatment with estradiol at a broad
range of concentrations, ranging from 0.001 to 100
lM (Fig. 1E). The addition of the potent estrogen re-
ceptor antagonist, ICI 182,780 (Fig. 1E), failed to
Fig. 1. Effect of genistein treatment on Hepcidin expression. (A and B) Zebrafish embryos were treated from 28 to 52 hpf with either estradiol
(E2), genistein, apigenin, daizdein, or genistin, each at 7 lM, and/or dorsomorphin (40 lM), followed by fixation for whole-mount in situ hybrid-
ization (A) or quantitative real-time RT-PCR (B) to assess hepcidin RNA levels. Hepcidin expression was consistently increased in intensity and
extent in the genistein-treated embryos, compared to DMSO-treated controls, but this effect was abrogated by cotreatment with dorsomorphin
(N5 36 per group). Arrowheads mark the liver and arrows mark the proximal intestine. Scale bar5 100 microns. For quantitative real-time RT-
PCR, data shown are means 6 standard error. N5 3 samples per group. *P< 0.05, compared to DMSO alone. (C-E) Hepcidin expression
measured by quantitative real-time RT-PCR in human hepatoma (HepG2) cells after treatment with a variety of chemicals at 10 lM (C), with ge-
nistein from 0 to 20 lM (D), or (E) estradiol (E2) from 0 to 100 lM in the presence or absence of the estrogen antagonist, ICI 182,780 (ICI;
100 lM). N5 2-4 samples per condition. *P< 0.05, compared to DMSO treated. (F) Treatment with genistein for 24 hours failed to increase
nontransferrin-bound iron (NTBI) uptake or transferrin-bound iron (TBI) uptake, as measured by 55Fe content per microgram of protein extracted
from HepG2 cells. N5 2 per group. *P< 0.05, compared to DMSO treated.
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inhibit genistein’s positive effects on Hepcidin tran-
script levels. In fact, the addition of the estrogen-recep-
tor inhibitor, ICI 182,780, actually increased Hepcidin
expression (Fig. 1E), suggesting that inhibition of
estrogen receptor signaling may enhance Hepcidin tran-
script levels.
Genistein Does Not Increase Hepatocyte Iron
Uptake. We considered the possibility that genistein
may increase Hepcidin expression by promoting cellular
iron loading. To evaluate this hypothesis, we tested the
effect of genistein on 55Fe uptake in HepG2 cells. After
24 hours of treatment with genistein, transferrin-bound
iron uptake was significantly reduced, compared to ve-
hicle alone (37.276 6.29 versus 67.216 2.755;
P< 0.05), whereas nontransferrin-bound iron uptake
was not significantly changed from vehicle-treated con-
trols (Fig. 1F). To evaluate effects on hepatocyte iron
stores (Supporting Fig. 5), we measured cellular ferritin
levels after 24 hours of treatment with genistein or
DMSO. We found no significant difference in ferritin
levels (0.1716 0.058 versus 0.1656 0.026; P5 0.92),
suggesting that the genistein-induced decrease in trans-
ferrin-bound iron uptake is offset by a hepcidin-
induced decrease in ferroportin-dependent iron export.
Genistein Increases Hepcidin Promoter Activi-
ty. Because genistein did not appear to cause increased
Hepcidin expression by enhancing cellular iron uptake,
we theorized that it could enhance the effect of either of
the major transcription factor pathways that have been
implicated in Hepcidin’s regulation: Smad4 or Stat3 sig-
naling. To interrogate these pathways, we transfected
HepG2 cells with reporter constructs encoding 3 kb of
the human Hepcidin promoter upstream of the firefly lu-
ciferase reporter gene. The promoter sequence was either
wild type (WT), mutated in the Stat3-binding site,
mutated in the Smad4-binding BREs, or mutated in
both the Stat3-binding motif and the BREs.33 We found
that treatment with either genistein or BMP6 for 6
hours enhanced Hepcidin-luciferase activity by two-fold
and three-fold, respectively (Fig. 2A). Mutation of the
Smad4-binding BREs, with or without mutation of the
Stat3 motif, decreased Hepcidin promoter activity below
basal levels in all conditions. However, mutation of the
Stat3 motif significantly impaired induction of Hepcidin
promoter activity in the genistein-treated, but not the
BMP6-treated or vehicle-treated, cells. Thus, the genis-
tein-induced increase in Hepcidin promoter activity
required Stat3 as well as Smad4 binding.
Inhibition of Type I BMP Receptor Activity
Decreases Genistein’s Effect on Hepcidin Expres-
sion. Dorsomorphin is a specific inhibitor of type I
BMP receptors that has previously been shown to
impair Hepcidin expression.35 Although treatment with
dorsomorphin alone greatly reduces Hepcidin expres-
sion, as measured by quantitative real-time RT-PCR
in HepG2 cells, cotreatment with genistein and dorso-
morphin allows the Hepcidin transcript level to remain
significantly above the basal level of expression
(1.86 0.15 versus 0.996 0.39; P< 0.05; Fig. 2B).
These observations imply that genistein activates both
BMP-dependent and BMP-independent pathways.
Genistein Treatment Is Associated With Increased
Transcript Levels of Many Genes That Are Up-Regu-
lated by BMP6. To compare the effects of genistein
and BMP6 on transcription in HepG2 cells, we per-
formed high-thoughput RNA-seq and identified the
transcripts up-regulated in HepG2 cells after treatment
with genistein (10 lM) or BMP6 (50 ng/mL) for 24
hours, in comparison to treatment with vehicle alone.
We found that genistein treatment significantly up-
regulated 2613 messenger RNA (mRNA) transcripts,
whereas BMP6 treatment significantly increased expres-
sion of 974 RNA transcripts. Using Kyoto Encyclope-
dia of Genes and Genomes (KEGG) pathway analysis,
we identified genistein-induced increases in transcripts
of genes affecting the ribosome, cell cycle, spliceosome,
acute and chronic myeloid leukemia, and the lysosome
(Table 1). Among the genes in the leukemic pathway
were the transcription factors, Stat3 and TGFb1, which
are known to affect Hepcidin expression.24-27,36 KEGG
pathways that were down-regulated after genistein
treatment (Supporting Table 2) included those affecting
valine, leucine, and isoleucine catabolism, fatty acid
metabolism, steroid biosynthesis, and the peroxisome
proliferator-activating receptor-signaling pathway.
We found that approximately two thirds of the tran-
scripts that were up-regulated by BMP6 were also up-
regulated by genistein, as illustrated in a Venn diagram
(Fig. 2C) and heat map (Fig. 2D). Gene Ontology
(GO) classification using the DAVID algorithm indi-
cated that genistein and BMP6 both affect 48 funda-
mental cellular processes (Supporting Table 3),
including translation and stress response, whereas
KEGG pathway analysis demonstrated that both genis-
tein and BMP6 increase transcript levels of ribosomal
proteins (Supporting Table 4).
To validate the results of the RNA-seq analysis, we
performed quantitative real-time RT-PCR to detect
changes in transcript levels in genes that exhibited
increased expression on RNA-seq after genistein treat-
ment (Fig. 3A-E). We found a significant correlation
between the natural log of the fold change in gene
expression, as measured by quantitative PCR and
RNA-seq (R25 0.7964; Fig. 3A). Genistein
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significantly increased transcript levels of Stat3 and the
TGFb1-responsive37,38 gene, Serpine1, also known as
plasminogen activator inhibitor type 1. In contrast,
BMP6 treatment did not induce expression of either
Stat3 or Serpine1 (Fig. 3B,C). Genistein treatment pro-
duced significant increases in the BMP-regulated17,39,40
transcripts, Id1 and Id3 (1.686 0.11 [P5 0.009] and
2.116 0.21 [P5 0.01], respectively), but these
increases (Fig. 3D,E) were far lower than the increases
produced by BMP6 (8.46 0.44 [P< 0.001] and
15.36 1.49 [P< 0.001], respectively). As expected,
the BMP receptor antagonist, dorsomorphin, repressed
transcript levels of Id1 and Id3.
To evaluate genistein’s effect on the Stat3-signaling
pathway, in comparison to IL-6 and BMP6, we used
quantitative real-time RT-PCR to assess changes in
gene expression of Stat3-related genes that were up-
regulated by genistein on RNA-seq (Fig. 4A-E). Genis-
tein, BMP6, or IL-6 each produced significantly
increased transcript levels of Hepcidin; however, only
genistein and IL-6 increased transcript levels of the
Stat3 target genes, suppressor of cytokine signaling 3
(SOCS3) and vascular endothelial growth factor A
(VEGFa), the Stat2-interacting protein, interferon reg-
ulatory factor 9 gene (IRF9), and IL6 receptor alpha.
In addition, genistein and IL-6 each up-regulated
TGFb1 (Fig. 4F).
Genistein Increases Stat3 Binding to the Hepcidin
Promoter. Because genistein up-regulated several
Stat-related genes and mutation of the Stat3-binding
Fig. 2. Effect of genistein and BMP6 on Hepcidin promoter activity and transcriptional profile. (A) Hepcidin promoter luciferase assay. HepG2
cells were cotransfected with a Renilla control vector (pRL-CMV) and either a construct containing a 3-kb WT human Hepcidin promoter upstream
of a firefly luciferase reporter (pink) or the same construct with inactivating mutations in the Stat3-binding site (orange), in the BMP response
elements (light green), or in both the Stat3-binding site and the BMP response elements (dark green). One day after transfection, cells were
treated for 6 hours with vehicle (1% DMSO), genistein (10 lM), or BMP6 (50 ng/mL), followed by lysis and measurement of luciferase activity.
Hepcidin promoter activity was reported as the ratio of firefly to Renilla activity and normalized to the WT Hepcidin promoter activity in the pres-
ence of vehicle only. Data shown are means 6 standard error. N5 4 samples per group. (B) The BMP receptor antagonist, dorsomorphin, signif-
icantly reduces genistein’s effect on Hepcidin expression, as measured by quantitative real-time RT-PCR in HepG2 cells treated for 18 hours with
vehicle (1% DMSO), dorsomorphin (10 lM), genistein (10 lM), or genistein and dorsomorphin combined (10 lM of each). N5 3 samples per
group. *P< 0.05, compared to DMSO treated. (C) Venn diagram illustrating results of RNA-seq. Nine hundred and seventy-four transcripts were
up-regulated in HepG2 cells after treatment with BMP6 (50 ng/mL), and 2,613 transcripts were up-regulated by genistein (10 lM), compared
to treatment with 1% DMSO. Of the genes up-regulated by BMP6, 662 were also up-regulated after treatment with genistein (10 lM), corre-
sponding to 48 GO groups. All treatments were performed for 18 hours before harvesting cells for RNA extraction. The numbers of biological rep-
licates were 3 (DMSO), 3 (genistein), and 2 (BMP6). (D) Heat maps displaying average fold-change in gene expression, relative to DMSO-
treated cells, in the RNA-seq experiment after treatment with BMP6 (top) or genistein (bottom). In each heat map, genes were ordered from low-
est to highest intensity of expression in BMP6-treated cells. Green corresponds to 0.125 fold-change, whereas red corresponds to 8-fold
change in expression over DMSO-treated controls. Gene expression was quantified as FKPM using the Cufflinks algorithm.
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site in the Hepcidin promoter impaired genistein’s
effect on Hepcidin promoter activity, we hypothesized
that genistein would increase Stat3 binding to the Hep-
cidin promoter. We performed immunoprecipitation
with a Stat3-specific Ab or with nonspecific IgG, fol-
lowed by quantitative RT-PCR, to amplify the Stat3-
binding site. We found that genistein significantly
increased Stat3 binding to the Hepcidin promoter
(9.26 3.16 versus 0.946 0.11; P5 0.004), whereas
BMP6 did not (Fig. 5A).
Genistein Increases Stat3 Phosphorylation. To
assess the effect of genistein on Stat3 activation in
human hepatocytes, we treated HepG2 cells with ge-
nistein or IL-6 and assessed the ratio of pStat3 to
Stat3 protein from 0 to 60 minutes after the start of
treatment (Fig. 5B). We found that genistein signifi-
cantly increased pStat3/Stat3 over the vehicle control
after 60 minutes of treatment (3.656 0.95 versus
1.036 0.21; p5 0.02). As expected, IL-6 also signifi-
cantly increased pStat3/Stat3 (2.816 0.56 versus
1.006 0.24; P5 0.01), but the effect peaked after 30
minutes of treatment.
Discussion
In our study, we identified genistein as the first
small-molecule experimental drug to up-regulate Hepci-
din transcript levels in vivo and in vitro. Genistein is
known to cause both estrogen receptor-dependent and
receptor-independent effects. Genistein exhibits estro-
genic effects on gene transcription,41-43 scavenges free
radicals,44 and inhibits numerous protein tyrosine
kinases.29 We found that genistein’s effect on Hepcidin
expression was estrogen receptor independent. Estradiol
failed to increase Hepcidin expression in either zebrafish
embryos or HepG2 cells, and the potent estrogen re-
ceptor inhibitor, ICI 182,780, failed to block genis-
tein’s effect. In fact, we found that ICI 182,780
stimulated Hepcidin expression. These observations
agree with recently published data indicating that
Fig. 3. Validation of RNA-seq data by quantitative real-time RT-PCR. (A) Graph of correlation between the natural log of the fold-change in
gene expression after genistein treatment for RNA-seq versus quantitative real-time RT-PCR analysis. Linear regression to determine the best-fit
line and Pearson’s coefficient R was performed using GraphPad 5.0 (GraphPad Software, Inc., La Jolla, CA). Yellow error bars include the 95%
confidence interval from the best-fit line. (B-E) Quantitative real-time RT-PCR to measure the change in expression of genes that were up-regu-
lated on RNA-seq analysis after treatment with genistein, including (B) Stat3, (C) Serpine1, (D) Id1, and (E) Id3. N5 3 per group. *P< 0.05,
compared to DMSO treated.
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estradiol does not increase Hepcidin expression, and
that ICI 182,780 increases Hepcidin transcript levels in
HepG2 cells in the presence or absence of estradiol.45
Hepcidin exerts control over iron homeostasis by
decreasing intestinal iron absorption and macrophage
iron release in response to excessive accumulation of
iron in vital organs. Hepatic iron overload increases
hepcidin transcript levels in normal mice46 and
humans.46 Thus, we hypothesized that genistein might
increase Hepcidin expression by enhancing hepatocyte
iron uptake. We found that genistein failed to increase
either transferrin-bound or nontransferrin-bound iron
uptake. Thus, genistein does not appear to increase
cellular iron overload, which is encouraging in a
potential therapy for hemochromatosis.
Our in vivo zebrafish and human hepatocyte data
(Figs. 1 and 2) indicate that BMP signaling is required
for hepcidin expression, and that genistein’s effect on
hepcidin expression is diminished by the BMP antago-
nist, dorsomorphin. Although our RNA-seq data indi-
cate that genistein up-regulated 68% of the genes that
were up-regulated by BMP6, genistein’s mode of
action differed from BMP6’s. Genistein increased Hep-
cidin promoter activity in a Stat3-dependent manner,
whereas BMP6 did not. We also identified several
genes in the Janus kinase/Stat-signaling pathway that
were up-regulated by genistein, but not by BMP6. For
example, Stat3 itself, IL6 receptor, SOCS3, Serpine1,
and VEGFa, all of which are up-regulated in response
to Stat3 activation,47 and IRF9, which interacts with
Stat2 (reviewed elsewhere48). Increasing IL6 receptor
expression would be expected to increase sensitivity to
IL6, which, in turn, could promote Hepcidin expres-
sion. Genistein also increased the expression of TGF-
b1, a Smad4-signaling protein that has been shown to
increase Hepcidin expression.36
Previously, genistein has been reported either to pro-
mote or inhibit Stat3 phosphorylation. This apparently
paradoxical effect appears to be dose dependent. At
lower concentrations, such as those used in our study,
genistein promotes Stat3 phosphorylation and cell pro-
liferation,49 whereas at high concentrations (40-50
Fig. 4. Effect of genistein on Stat3-related genes and TGF-b1 in HepG2 cells. (A-F) Quantitative real-time RT-PCR comparing changes in
mRNA expression in HepG2 cells after treatment for 24 hours with genistein (10 lM), BMP6 (50 ng/mL), or IL-6 (100 ng/mL) in (A) Hepcidin,
(B) SOCS3, (C) IRF9, (D) VEGFa, (E) IL6 receptor, and (F) TGFb1. N5 2-6 per group. *P< 0.05, compared to DMSO treated.
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lM) genistein inhibits Stat3 phosphorylation and cell
proliferation49,50 and promotes apoptosis.49 Consistent
with these observations, we found that 10 lM of ge-
nistein enhanced Stat3 phosphorylation and Stat3
binding to the Hepcidin promoter in cultured human
hepatocytes.
We have demonstrated that genistein increases
hepcidin expression in human hepatocytes in a Stat3-
dependent and Smad4-dependent manner. The screen-
ing technique that we have developed may be used to
identify other Hepcidin regulatory molecules with dif-
ferent modes of action. Genistein and other candidate
molecules may subsequently be tested in preclinical
models of iron overload syndromes and used to de-
velop new therapies for iron overload.
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